Genetic Technologies Reports Q2 FY22 Cash Flow Results

2 years ago

Q2 momentum sets the stage for a strong FY22MELBOURNE, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:…

Clearmind Medicine to Host “Psychedelic for Alcoholism: From Molecule to Medicine” Virtual Event on January 26

2 years ago

Clearmind’s Management Team Will Explain the Regulatory Process Required for Clearmind’s Patented MEAI Molecule to Become an FDA Approved Medicine…

Allied Corp Signs Supply Agreement for 1000KGS Monthly and Completes Manufacturing Process for Allied Inside™ Veteran Focused CBD Cigarette

2 years ago

KELOWNA, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to…

Third North Carolina Hospital System Signs New Contract for Streamline Health® eValuator™

2 years ago

Coastal Medical Center Chooses Automated Coding Analysis for Inpatient and Outpatient Care to Improve Revenue Performance Atlanta, GA, Jan. 19,…

AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

2 years ago

Live video webcast presentation on Wednesday, January 26th at 10:00 AM ETOCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM…

Quad M Solutions Inc. Signs MOU with Quantum Computing Inc.

2 years ago

Will Deliver the First Quantum Solution for Medical Underwriting Edgewater, NJ, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Quad M solutions,…

FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

2 years ago

New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods…

ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

2 years ago

-- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI),…

Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

2 years ago

Live video webcast presentation on Tuesday, January 25th at 3:00 PM ETISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook…

Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

2 years ago

New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7…